
LifeMD (LFMD) Stock Forecast & Price Target
LifeMD (LFMD) Analyst Ratings
Bulls say
LifeMD is expected to achieve a 12-month price target of $10 per share due to its strong sales and expanding services in core areas such as Women's Health and weight management, in addition to strategic partnerships with major pharmaceutical companies. However, competition and potential risks, as well as a negative adjusted EBITDA in the first quarter of 2026, may affect reaching this target. Overall, the company's growth and collaborations show promise, but investors should carefully consider potential risks before making investment decisions.
Bears say
LifeMD is heavily investing in unapproved peptides, which may offer high margins, but carry potential risks due to lack of FDA approval. While the company expects strong revenue and EBITDA growth in the future, there are significant risks that could hinder their success, including cybersecurity threats, product recalls, and overall market demand. With a highly regulated healthcare market and a history of losses, there are uncertainties surrounding the company's ability to maintain profitability and effectively execute their growth strategies.
This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.
LifeMD (LFMD) Analyst Forecast & Price Prediction
Start investing in LifeMD (LFMD)
Order type
Buy in
Order amount
Est. shares
0 shares